Tony Di Bona is Chief Financial Officer and General Partner of Alloy Ventures and is a founding member of the firm. Tony is in charge of all finance, accounting, and computer operations for Alloy, and assists in financial due diligence. He also assists portfolio companies with their accounting, financial reporting, and computing systems.
Tony’s career in venture capital started in 1988, when he joined Craig Taylor and John Shoch at Asset Management Associates. When Craig and John co-founded Alloy Ventures in 1996, Tony Di Bona became CFO and General Partner of the new firm. Previously, Tony served as CFO for an Australian retail firm, helping the company open its U.S. operation. Tony is an expert in the use of open source computer systems, networks, and leverages his technology and financial expertise to help Alloy evaluate investment opportunities in computer-related markets. He received a BEc, majoring in accounting and law, at Sydney University (1982).
He also serves on the Board of the Northern California Private Equity & VC Chapter of the Financial Executive Alliance, a national affinity group administered by First Republic Bank. He currently is a Partner at Redbrick Associates .
Leighton Read was a Managing Member in four Alloy funds investing with us in companies from 2001-2007, and now serves as a Venture Partner. Before joining Alloy, Leighton spent 14 years as a biotechnology entrepreneur and investor. He co-founded Affymax NV, under the direction of Dr. Alejandro Zaffaroni, setting the stage for two successful spin-outs: Affymetrix and Maxygen. He founded Aviron, a biotechnology company best known as the developer of FluMist™, the intranasal influenza vaccine, where he served as Chairman and CEO until 1999 and Director until its acquisition by MedImmune in 2002. While at Alloy, he served as the first CEO of Avidia, a spin-out of Maxygen later acquired by Amgen. For over two decades, he has also been interested in the psychological principles that underlie successful electronic games and is currently devoting substantial time to his role as Chairman of Seriosity, a start-up leading in the application of game principles to the challenges of large enterprises. He received a B.S. from Rice University in Psychology and Biology (1973), an MD from the University of Texas Health Science Center at San Antonio (1976) and completed internal medicine training at Duke and the Peter Bent Brigham Hospital in Boston where he held appointments at the Harvard Medical School and School of Public Health. His research dealt with applications of decision theory in medicine, cost-effectiveness analysis and policy regarding medical innovation.
Leighton is a director of Siluria. He also serves as a trustee or director of The BeneTech Initiative, BioVentures for Global Health, and the Santa Fe Institute. His awards include several as co-inventor of technology underlying the Affymetrix GeneChip.
David W. Pidwell has been a venture partner at Alloy Ventures since 1996. In 1987, he founded Rasna Corp., a mechanical design automation software company financed by the partners at Alloy. He was President and CEO until 1995 when Parametric Technology (Nasdaq: PMTC) acquired the firm. Prior to Rasna, Mr. Pidwell worked for ROLM Corp. for 14 years. He is currently a director of Xactly, and Informatica (Nasdaq: INFA). He received a BS in electrical engineering (1969) and a MS in computer systems engineering (1970) from Ohio University and completed three years of work at Stanford University on a PhD in engineering economic systems.